AAA
ASMB icon

Affinity Asset Advisors’s Assembly Biosciences ASMB Stock Holding History

Affinity Asset Advisors’s Portfolio ASMB Stock Details ASMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.22M Buy
+190,000
New +$5.17M 0.24% 77

Other funds holding ASMB

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Affinity Asset Advisors's ASMB Position: Q2 2026 in Review

Affinity Asset Advisors opened a new position in Assembly Biosciences (ASMB) in Q2 2026: 190,000 shares worth $5.22M. The stake represents 0.24% of the portfolio and ranks #77 among its holdings.

43 funds tracked by Wall St. Rank hold ASMB as of Q2 2026.

  • Affinity Asset Advisors held 190,000 shares of Assembly Biosciences worth $5.22M as of Q2 2026.
  • Assembly Biosciences was a new Affinity Asset Advisors position in Q2 2026.
  • Assembly Biosciences made up 0.24% of Affinity Asset Advisors's portfolio in Q2 2026, its #77 holding.
  • 43 funds tracked by Wall St. Rank held Assembly Biosciences as of Q2 2026.

Based on Affinity Asset Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.